The Myth of the Free Market for Pharmaceuticals

N Engl J Med. 2024 Apr 25;390(16):1448-1450. doi: 10.1056/NEJMp2313400. Epub 2024 Apr 20.

Authors

Rena M Conti¹, Richard G Frank¹, David M Cutler¹

Affiliation

¹ From the Questrom School of Business, Boston University, Boston (R.M.C.), and the Conference on Research in Income and Wealth (R.M.C.), the National Bureau of Economic Research (R.G.F., D.M.C.), and the Department of Economics, Harvard University (D.M.C.), Cambridge - all in Massachusetts; and the Brookings Institution, Washington, DC (R.G.F.).

PMID: 38647106
DOI: 10.1056/NEJMp2313400

No abstract available

MeSH terms

Commerce* / economics
Commerce* / legislation & jurisprudence
Drug Costs / legislation & jurisprudence
Drug Industry* / economics
Drug Industry* / legislation & jurisprudence
Economics, Pharmaceutical* / legislation & jurisprudence
Health Policy* / economics
Health Policy* / legislation & jurisprudence
Humans
Patents as Topic / legislation & jurisprudence
Pharmaceutical Preparations* / economics
United States
United States Food and Drug Administration / economics
United States Food and Drug Administration / legislation & jurisprudence

Substances

Pharmaceutical Preparations